

TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENTS	iii
ABSTRACT (ENGLISH)	vi
ABSTRACT (THAI)	ix
LIST OF TABLES	xxi
LIST OF FIGURES	xxii
ABBREVIATIONS AND SYMBOLS	xxv
CHARTER 1 INTRODUCTION	1
1.1 Statement and significance of the problem	1
1.2 Literature review	5
1.2.1 Antibody-based therapeutic for HIV/AIDS therapy	5
1.2.1.1 HIV-1 and AIDS	5
1.2.1.2 A standard regimen of HIV/AIDS treatment	5
1.2.1.3 Antibodies and antibody fragment	7
1.2.1.4 Therapeutic antibodies of HIV treatment	9
1.2.2 Role of HIV matrix (MA) protein in HIV life cycle	11
1.2.3 The effective antibody against MA (anti-MA mAb HB-8975)	16
1.2.4 Recombinant protein expression	17

1.2.4.1	Recombinant protein expression in <i>E. coli</i>	17
1.2.4.2	Recombinant protein expression in insect cell via baculovirus expression system	22
1.2.5	Phage display technology	23
1.2.5.1	Introduction	23
1.2.5.2	Biology and structure of M13 filamentous bacteriophage	24
1.2.5.3	M13 filamentous bacteriophage	26
1.2.5.4	Filamentous phage-based vector system	31
1.2.5.5	Applications of phage display	33
1.2.6	Computational approaches and structural-based protein analysis	36
1.2.6.1	Homology modeling	36
1.2.6.2	Molecular modeling	38
1.2.6.3	Molecular dynamic simulations (MDs) and binding free energy calculation	40
1.2.7	<i>In vitro</i> display technology	40
1.2.8	Baculovirus display technology	43
1.2.8.1	Baculovirus (BV)	43
1.2.8.2	Biology and structure of budded baculovirus	43
1.2.8.3	Major membrane glycoprotein	45
1.2.8.4	Baculovirus entry	46
1.2.8.5	Baculovirus applications	47

1.2.8.6 Baculovirus display technology	49
1.2.9 HIV-1 protease (HIV-PR)	52
1.2.9.1 HIV-PR structure and mechanism	52
1.2.9.2 HIV-PR inhibitors	55
1.2.9.3 HIV-PR resistant strains	58
1.2.9.4 Drug discovery	59
1.3 Objectives	60
CHAPTER 2 MATERIALS AND METHODS	61
2.1 Chemicals and equipments	61
2.2 <i>E. coli</i> strains and vectors	61
2.3 Cell culture	62
2.4 Computational assisted modeling	62
2.4.1 Homology modeling	63
2.4.2 Molecular docking	64
2.4.3 Molecular dynamics (MD) simulations and binding free energy calculatio	65
2.5 Construction of the gene encoding scFv-MA HB-8975	66
2.5.1 Extraction and quantification of total RNA from hybridoma cell producing anti-MA mAb HB-8975	66
2.5.2 The generation of scFv-MA HB-8975 fragment	67
2.6 Construction of phagemid vector encoding scFv-MA HB-8975	69

2.6.1	Construction of pComb3X-SS processing scFv-MA HB-8975	69
2.6.2	Phagemid purification by using alkaline lysis method	69
2.6.3	Characterization of recombinant clones	70
2.7	Production of phage-displayed scFv-MA HB-8975	71
2.7.1	Phage production	71
2.7.2	Harvesting phage by polyethylene glycol (PEG) precipitation	71
2.7.3	Phage-displayed scFv-MA HB-8975 titration by <i>E. coli</i> infection	72
2.7.4	Determining of phage expressing scFv-MA HB-8975 by SDS-PAGE and Western immunoblotting	73
2.8	Preparation of soluble scFv-MA HB-8975 protein	74
2.8.1	Production of soluble scFv-MA HB-8975 protein	74
2.8.2	Western blotting	74
2.9	Evaluation of the binding activity of phage-displayed scFv anti-MA HB-8975 and soluble scFv-MA HB-8975 with HIV-1 MA epitope variants by ELISA	75
2.9.1	Indirect ELISA	75
2.9.2	Competitive ELISA	76
2.10	Construction and evaluation of scFv-MA HB-8975 mutants	77

2.10.1	Site-specific mutagenesis of scFv-MA HB-8975	77
2.10.2	Production of phage-displayed and soluble scFv-MA HB-8975 mutants	78
2.10.3	Evaluation of the binding activity of phage-displayed and soluble scFv-MA HB-8975 mutants by ELISA	79
2.11	Engineering of the gene encoding scFv-MA HB-8975 in baculovirus expression system	79
2.11.1	Construction of two versions of scFv-MA Hb-8975	79
2.11.2	Production of recombinant scFvE2/MA and scFvG2/MA in Sf9 cells	80
2.11.3	Purification of scFv-MA HB-8975 from infected Sf9 cells	83
2.12	Localization of scFv-MA on infected Sf9 cells	84
2.12.1	Cell fractionation	84
2.12.2	Flow cytometry	85
2.13	Baculovirus-displayed scFv-MA particle	85
2.13.1	Isolation of BV	85
2.13.2	Western blotting of BV particles	86
2.13.3	Electron microscopy	87

2.14	Evaluation of purified- and baculovirus-displayed scFv-E2MA And scFvG2/MA by ELISA	87
2.14.1	Indirect ELISA	87
2.14.2	Competitive ELISA	88
2.15	Production and evaluation of baculovirus-displayed scFv-M61B9	90
2.15.1	Vector construction and baculovirus display production	90
2.15.2	Indirect ELISA	90
2.16	Construction and expression of HIV-PRH ₆	91
2.16.1	Vector construction	91
2.16.2	Expression of HIV-PRH ₆ in <i>E. coli</i>	92
2.17	Production of H ₆ MA-CA substrate by baculovirus- expression system	93
2.17.1	Vector construction	93
2.17.2	Preparation of recombinant H ₆ MA-CA protein in Sf9 cells	94
2.18	Production of monoclonal antibodies	94
2.18.1	Mouse immunization	94
2.18.2	Hybridoma technique	95
2.19	Purification of monoclonal antibodies	96

2.20	Characterization of monoclonal antibodies by indirect ELISA and Western blotting	96
2.20.1	Indirect ELISA	96
2.20.2	Western blotting	97
2.21	Development of ELIS-based HIV-PR activity assay (ELIB-PA)	98
2.21.1	HIV-RR activity assay by ELIB-PA	98
2.21.2	The efficacy of ELIB-PA with HIV protease inhibitors	99
CHAPTER 3 RESULTS		101
Study 1:	Characterization of the key amino acid residues of a single chain variable fragment against HIV-1 matrix protein (MA) or scFv-MA HB-8975 by computational approaches	101
3.1	Homology modeling of scFv-MA HB-8975	101
3.2	Evaluation of the scFv-MA HB-8975-peptide complexes by molecular docking	104
3.3	Construction of phagemid vector encoding scFv-MA HB-8975	107
3.4	Detection of phage particles displaying scFv-MA HB-8975 and soluble scFv-MA HB-8975	108
3.5	Characterization of phage-displayed scFv-MA HB-8975 And soluble scFv HB-8975	110

3.6	Comparison of calculated binding free energy from computational assisted model and experimental data	112
3.7	Decomposition of energy on the amino acid residues in CDRs And specific contact upon binding	115
3.8	Verification of computational data by site directed mutagenesis	121
Study 2:	Generation of recombinant baculovirus-displayed scFv-MA HB-8975 by the novel leader sequence	125
3.9	Construction of scFv-MA HB-8975 in baculovirus-expression system	125
3.10	Production of baculovirus carrying scFv gene and expression Of recombinant scFv in BV-infected Sf9 cells	126
3.11	Cellular distribution of scFvE2/MA and scFvG2/MA in recombinant BV-infected Sf9 cells	129
3.12	Characterization of purified scFvE2/MA and scFvG2/MA	133
3.13	Biophysical status of scFvE2/MA on the baculovirus	136
3.14	Immuno-EM analysis of baculovirus progeny of BV-scFvE2/MA	138
3.15	Immunological functionality and topology of scFvE2/MA displayed on baculovirus envelope	140

3.16	Baculovirus-displayed scFv-M61B9 against CD147 molecules	142
3.16.1	Immuno-electron microscopy	142
3.16.2	Indirect ELISA	143
3.17	A scheme of the general strategy of BV particle using a novel leader octadecapeptide N18E2	146
Study 3:	Development of a simplified enzyme-linked immunosorbent-assay (ELISA) for the HIV-1 protease (HIV-PR) activity	148
3.18	Design of the ELIS-based HIV-PR activity assay (ELIB-PA)	148
3.19	Construction of a plasmid vector encoding HIV-PRH ₆	150
3.20	Production and solubility of HIV-PRH ₆ in E. coli	152
3.21	Production and purification of recombinant H ₆ MA-CA protein in Sf9 cells	154
3.22	Production and characterization of monoclonal antibodies to CA and to MA epitope embedded in H ₆ MA-CA	156
3.23	Evaluation of the ELIS-based HIV-PR activity assay (ELIB-PA)	159
3.24	Efficacy and sensitivity of ELIB-PA	162
	CHAPTER 4 DISCUSSION	166
	CHAPTER 5 CONCLUSION	181
	REFERENCES	184
	APPENDICES	217

APPENDIX A List of the chemicals and instruments	218
APPENDIX B List of cell lines and microorganisms	225
APPENDIX C List of antibodies and conjugated antibodies	226
APPENDIX D List of enzymes	227
APPENDIX E Reagent preparations	228
APPENDIX F Presentations and publications	244
CURRICULUM VITAE	246

LIST OF TABLES

Table	Page
1.1 Phage coat proteins	26
1.2 Classification of phage-display vectors	32
1.3 Mutations in the protease gene associated with resistance to PIs	58
2.1 The amino acid sequences of nine synthetic C-terminal-MA epitope peptides	65
2.2 Primers for construction of scFv-MA HB-8975 fragment	68
2.3 Primers for generation of scFv-MA mutants	78
2.4 Oligonucleotides for construction of two versions of scFv-MA HB-8975 fragment in baculovirus expression system	80
2.5 The HIV-1 MA epitope peptides of natural variants	89
3.1 PMF scores and residues on CDR loops of scFv-MA HB-8975 at 4.5 Å from each of nine peptide epitopes	106
3.2 Relationship between the binding activity from competitive ELISA and those from MM-PBSA methodology	115
3.3 Common interacting residues found among the nature peptide sequences in the docking study	118
3.4 Comparison of the binding affinity of scFv-MA HB-8975 and scFv-MA-M100G by percentage inhibition value	124

LIST OF FIGURES

Figure	Page
1.1 Antibodies and antibody fragments	8
1.2 How antibodies combat HIV-1	10
1.3 Schematic representation of modes of intrabody action against potential therapeutic targets in HIV-1 infected	12
1.4 Role of MA protein in HIV life cycle	14
1.5 Structure and maturation of the HIV-1 virion	15
1.6 Diagram of the secretion pathways of <i>E. coli</i>	18
1.7 The general Sec pathway in bacteria	21
1.8 Structure of a filamentous bacteriophage	25
1.9 Model of filamentous phage infection	29
1.10 M13 bacteriophage assembly	30
1.11 Schematic diagram of a filamentous phage displaying single chain-variable fragment (scFv) molecules	35
1.12 Schematic procedure of homology modeling	37
1.13 Schematic procedures of Molecular docking	39
1.14 Different display technology for selecting antibodies	41
1.15 Diagram of nucleopolyhedrovirus virions	44
1.16 Schematic representations of the baculovirus-display strategies	51
1.17 The crystal structure of the HIV-1 protease	53

1.18	Schematic representation of the HIV protease cleavage mechanism	54
1.19	Chemical structures of HIVPR inhibitors	57
2.1	Recombination between Bac-N-Blue™ DNA and pBlueBac-scFv-MA transfer vector	82
2.2	Formation of blue plaques	83
3.1	Molecular models of scFv-MA HB-8975	103
3.2	Schematic figure of pComb3X-scFv-MA phagemid vector	107
3.3	Verification of phage displayed scFv-MA HB-8975 and soluble scFv-MA HB-8975	109
3.4	Determining of the binding activity of phage-displayed scFv-MA HB-8975 and soluble scFv-MA HB-8975	111
3.5	Characterization of phage-displayed scFv-MA HB-8975 and soluble scFv-MA HB-8975 with HIV-1 MA mutant peptides	114
3.6A	List of the decomposed energies of the common amino acids in CDRs of scFv-MA HB-8975	119
3.6B	Residues interaction of final MD complex structure between scFv-MA HB-8975 and four peptide epitopes	120
3.7	Characterization of scFv-MA mutants	123
3.8	Amino acid sequences of scFvE2/MA and scFvG2/MA	125
3.9	Expression and solubility of scFvE2/MA and scFvG2/MA in Sf9 cells	128
3.10	Cellular localization of scFvE2/MA and scFvG2/MA in Sf9 cells	131
3.11	Immunological Characterization of scFvE2/MA and scFvG2/MA	135
3.12	BV display of scFvE2/MA (BV-E2/MA)	137


3.13	Immuno-electron microscopy of BV particles carrying scFvE2/MA (BV-E2/MA)	139
3.14	Topology and functionality of BV-displayed scFvE2/MA	141
3.15A	Immuno-electron microscopy of BV particles carrying chimeric scFv-N18E2/M6 (BV-N18E2/M61B9)	144
3.15B	Functional analysis of BV-displayed chimeric scFv-N18E2/M61B9	145
3.16	Generation of recombinant BV vector designed for display of scFv using the N18E2 signal peptide	147
3.17	Principle of the <i>in vitro</i> ELIS-based HIV-PR activity assay	149
3.18	Construction of an HIV-PRH ₆ expression vector and the amino acid-sequence of HIV-PRH ₆ and its variant	151
3.19	Expression of HIV-PRH ₆ and its variant in <i>E. coli</i>	153
3.20	Purification of recombinant H ₆ MA-CA protein using Ni ²⁺ -NTA-agarose column	155
3.21	Binding of anti-CA mAb G18 and anti-MA mAb HB-8975	158
3.22	Analysis of HIV-PRH ₆ activity using the ELIB-PA	161
3.23	Activity of HIV-PRH ₆ in the presence of HIV protease inhibitors	164

ABBREVIATIONS AND SYMBOLS

%	Percent
β	beta
$^{\circ}\text{C}$	Degrees Celsius
AIDS	Acquired immunodeficiency syndrome
AcMNPV	<i>Autographa californica</i> Multicapsid Nuclear Polyhedrosis Virus
Asp	Aspartate
bp	Base pair (s)
BSA	Bovine serum albumin
BV	Baculovirus (es)
CA	Capsid protein
cDNA	Complementary DNA
CDRs	Complementarity determining regions
cfu	Colony forming unit (s)
<i>E. coli</i>	<i>Escherichia coli</i>
EFV	Efavirenz
ELISA	Enzyme-linked immunosorbent assay
ELIB-PA	ELIS-based HIV-PR activity assay
DNA	Deoxyribonucleic acid
FBS	Fetal bovine serum
Gly	Glycine

HAART	Highly active antiretroviral therapy
hr	Hour (s)
HIV	Human Immunodeficiency virus-1
HIV-PR	Human Immunodeficiency virus-1 protease
His	Histidine
HCl	hydrochloric acid
HRP	horseradish peroxidase
Ig	Immunoglobulin
IPTG	isopropyl β -D-thiogalactopyranoside (IPTG)
kb	kilo base pair (s)
kDa	kilodaltons
LB	Luria-Bertani
Leu	Leucine
M	molar (s)
MA	Matrix protein
mAb	monoclonal antibody (-ies)
MDs	Molecular dynamic simulation
MgCl ₂	Magnesium Chloride
ml	milliliter (s)
Mw	Molecular weight
NaCl	Sodium chloride
NaN ₃	Sodium azide
NaOH	Sodium hydroxide

NC	Nucleocapsid protein
NFV	Nelfinavir
ng	Nanogram (s)
NNRTIs	Non-nucleoside reverse transcriptase inhibitors
nm	nanometer (s)
nM	nanomolar (s)
NRTIs	Nucleoside/nucleotide reverse transcriptase inhibitors
OD	Optical density
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
Phe	Phenylalanine
PIs	Protease inhibitor (s)
PMF	Potential of mean force score
RNA	Ribonucleic acid
rpm	revolutions per minute
RT	Reverse transcriptase
RTV	Ritonavir
scFv	Single-chain variable fragments
SD	standard deviation
Sf9	<i>Spodoptera Frugiperda</i>
SQV	Saquinavir
Tyr	Tyrosine



μg	microgram (s)
μl	microliter (s)
μm	micrometer (s)
μM	micromolar (s)
V_H	Variable regions of heavy chain
V_L	Variable regions of light chain
VSV-G	Vesicular stomatitis virus G glycoprotein
V/V	Volume /Volume
WHO	World Health Organization
W/V	Weight/Volume
X-gal	5-bromo-4-chloro-3-indoly- β -D-galactoside

ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่

Copyright© by Chiang Mai University
All rights reserved